- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Rheumatoid arthritis (RA)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Upadacitinib – November 2019
Upadacitinib: Tablet (modified release) 15 mg; Rinvoq®
Last updated
5 March 2021